SRI Capital has launched its debut fund, targeting innovative technology start-ups in the US and India, with a target of $100 million.
The fund is anchored by a $20 million commitment from the family office of founder and managing partner Sashi Reddi, who told VC Circle that the firm has already reached a first close of $40 million. Capital...
Hangzhou-based drug developer Sumgen Biotech has raised RMB220 million ($32 million) in a Series B funding led by Addor Capital.
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.